VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

Phase 3 Completed 204 enrolled Veru Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).

Timeline

Start: 2021-05-18
Primary completion: 2022-07-06
Completion: 2022-07-06

Publications

Barnette KG, Gordon MS, Rodriguez D, Bird TG, Skolnick A, Schnaus M, Skarda PK, Lobo S, Sprinz E, Arabadzhiev G, Kalaydzhiev P, Steiner M. Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. NEJM Evid. 2022 Sep;1(9):EVIDoa2200145. doi: 10.1056/EVIDoa2200145. Epub 2022 Jul 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sabizabulin	Small molecule	9 mg	Oral

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

Summary

Timeline

Publications

Drugs

Indications